Dr. Joseph Mikhael | CureTalks

Dr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF). He also serves as a Councilor on the Executive of the American Society of Hematology. He specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis and Waldenstrom’s macroglobulinemia. Dr. Mikhael is currently the principal investigator of many clinical trials, primarily in relapsed multiple myeloma, and incorporating immunotherapies into the treatment algorithm of this incurable disease. He has helped develop Isatuximab (a CD38 monoclononal antibody) from its infancy, soon to be in the clinic. His other clinical research interests also include pharmaco-economics, communication skills and media relations. He has published over 100 peer reviewed articles in these fields. He lectures internationally on a regular basis. He is an active member of the International Myeloma Working Group, and serves on the editorial board of JCO. Dr. Mikhael is also deeply involved in training future researchers, as he mentors junior hematologists nationwide. He was recently the co-chair of the American Society of Hematology Clinical Research Training Institute (CRTI). This is a week-long intense course designed to train up and coming clinical researchers in blood diseases and cancer. Dr. Mikhael works closely with Dr. Jonathon Keats and his lab at TGen.